3 Results for "

CDK1 Thr14 phosphorylation

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "CDK1 Thr14 phosphorylation" in MCE Product Catalog:

Cat. No.: HY-182906
CAS No.: 3040320-93-9
Target:  

Wee1 CDK

Research Areas:  

Cancer

XL495 is an potent, selective and orally active PKMYT1 inhibitor. XL495 inhibits CDK1 Thr14 phosphorylation and induces KAP1 Ser824 phosphorylation in xenograft tumors. XL495 reduces tumor growth in colorectal and breast cancer xenograft models, and achieves tumor regression with DNA-damaging agents in colorectal cancer xenograft models. XL495 can be used for the research of cancer, such as breast cancer and colorectal cancer .
loading...
    loading...
Cat. No.: HY-180485
Target:  

PROTACs Wee1 CDK

Research Areas:  

Cancer

PROTAC D16-M1P2 is an orally active CRBN-mediated selective PKMYT1 PROTAC degrader, with a DC50 of 0.7 nM in CCNE1-amplified HCC1569 breast cancer cells. PROTAC D16-M1P2 induces PKMYT1 degradation via the ubiquitin-proteasome system, directly inhibits PKMYT1 kinase activity, suppresses Thr14 phosphorylation of CDK1, and depends on functional CRBN and ubiquitination-like modification processes. PROTAC D16-M1P2 can be used for the research of CCNE1-amplified breast cancer, FBXW7-mutated cholangiocarcinoma, and PPP2R1A-deficient cancers .
loading...
    loading...
Cat. No.: HY-187562
Target:  

Wee1 CDK

Research Areas:  

Cancer

PKMYT1-IN-15 is an orally active PKMYT1 inhibitor with an IC50 of 6.02 nM. PKMYT1-IN-15 inhibits the phosphorylation of CDK1 at Thr14. As an antiproliferative agent, DNA damage inducer and antitumor agent, PKMYT1-IN-15 triggers replication-associated DNA damage and cell death in CCNE1-amplified cancer cells, and suppresses tumor growth in the OVCAR3 xenograft model. PKMYT1-IN-15 can be used for the research of CCNE1-amplified cancers (e.g., ovarian cancer, breast cancer) .
loading...
    loading...